Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €65.00 ($75.58) target price by research analysts at Deutsche Bank in a research report issued on Tuesday, April 9th, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Deutsche Bank’s price target points to a potential upside of 26.39% from the stock’s previous close.
A number of other research analysts also recently commented on the company. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, April 2nd. Independent Research set a €53.00 ($61.63) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, February 20th. UBS Group set a €46.00 ($53.49) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, January 9th. Credit Suisse Group set a €45.00 ($52.33) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, January 23rd. Finally, Berenberg Bank set a €70.95 ($82.50) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Monday, February 18th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of €59.23 ($68.88).
FRE traded up €0.68 ($0.79) on Tuesday, reaching €51.43 ($59.80). The company’s stock had a trading volume of 1,792,419 shares. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($69.95) and a 1 year high of €80.00 ($93.02).
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
See Also: Percentage Decliners
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.